Accumulation of major linezolid metabolites in patients with renal impairment

Ernane Souza, Ryan L. Crass, Jeremy Felton, Kengo Hanaya, Manjunath P. Pai

研究成果: Article査読

4 被引用数 (Scopus)

抄録

In patients with renal impairment (n=22 of 39), the median serum concentrations of linezolid, PNU-142300, and PNU-142586 were 1.6-, 3.3-, 2.8-fold higher, respectively, than in patients without renal impairment. Metabolite concentrations in paired samples were poorly correlated with linezolid concentrations (r2 = 0.26 for PNU-142300 and 0.06 for PNU-142586). Linezolid and its metabolites share potential toxicophores that deserve characterization to mitigate higher myelosuppression risk in patients with renal impairment.

本文言語English
論文番号e00027-20
ジャーナルAntimicrobial Agents and Chemotherapy
64
5
DOI
出版ステータスPublished - 2020 5 1

ASJC Scopus subject areas

  • 薬理学
  • 薬理学(医学)
  • 感染症

フィンガープリント

「Accumulation of major linezolid metabolites in patients with renal impairment」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル